Consensus Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 14:53:07 09/12/2025 GMT			5-day change	1st Jan Change
2,006.00 ^DKK	-2.43%		-0.39%	+35.75%

07:52am	Genmab shares encouraging early-stage data on epcoritamab for RT patients	RE
06:30am	Genmab Presents Promising Data for Epcoritamab in Richter's Transformation	FW

Evolution of the Average Target: Genmab A/S

Evolution of the Target Price: Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

de.oWCsmeStZKeC-r_LpID5DeQttzhjMANiQqcZnCN89oc.9SuV67PGC8juuPLy19-IX6N12lcRfzA3MPBtz1Q9oMjEJ-60gOo20vWq9g~57ce80de300723d1e84a8c6dfb102ee6

Analysts' recommendations: Genmab A/S

12-08	JP Morgan Raises Genmab Price Target to 2,050 Danish Kroner (from 1,650), Maintains Neutral Rating - BN	FW
11-14	Kepler Cheuvreux Kicks Off Genmab Coverage at Hold	MT
11-07	Genmab advances on earnings strength and pipeline while lower valuation opens upside
11-07	Truist Trims Price Target on Genmab to $48 From $49, Keeps Buy Rating	MT
11-03	Handelsbanken raises target price for Genmab to DKK 2,200 (2,000), reiterates buy recommendation - BN	FW
10-31	Nordea Raises Price Target for Genmab to 2,021 Danish Kroner, Reiterates Buy	FW
10-29	Jyske Bank Downgrades Genmab to Hold	MT
10-28	Jyske Bank Downgrades Genmab to Hold (from Buy), Sets Target Price at 2,000 Danish Kroner - BN	FW
10-24	Goldman Sachs Raises Target Price for Genmab to 1,996 Danish Kroner, Maintains Neutral Rating - BN	FW
10-20	Genmab Shares Drop on J&J Study Data Signaling Heightened Competition	FW
10-18	Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer	CI
10-17	Aktiespararna Recommends Buying Genmab Shares	FW
10-06	GENMAB : UBS raises target price
10-06	UBS Raises Price Target for Genmab to 2,700 Danish Kroner, Reiterates Buy	FW
10-06	Deutsche Bank Raises Genmab Target Price to 2,000 Danish Kroner, Reiterates Buy	FW
10-01	Canaccord Quest Updates Buy/Sell List: Truecaller and Betsson Removed from Buys, H&M Off Sells	FW
09-29	Genmab's $8 Billion Bid Represents 'Good Deal' for Merus' Petosemtamab, Truist Says	MT
09-29	GENMAB : A bold shift from defensive to aggressive
09-29	Sydbank raises Genmab to buy (hold) - BN	FW
09-29	Ålandsbanken: Genmab Pays Too High a Price for Merus	FW
09-11	JP Morgan Raises Target Price for Genmab to 1,650 Danish Kroner (from 1,500), Maintains Neutral Rating - BN	FW
09-08	Bernstein Raises Target Price for Genmab to 1,015 Danish Kroner, Reiterates Underperform	FW
08-28	Deutsche Bank Raises Genmab Price Target to DKK 1,900, Reiterates Buy	FW
08-20	Rothschild Lowers Price Target for Genmab to 2,650 Danish Kroner (from 2,700), Reiterates Buy - BN	FW
08-13	GENMAB : target price raised by UBS

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GENMAB A/S					+1.32%
	ARGENX SE					+0.85%
	INSMED INCORPORATED					+13.34%
	WUXI APPTEC CO., LTD.					+37.61%
	BIONTECH SE					+40.91%
	WUXI BIOLOGICS (CAYMAN) INC.					+19.71%
	AKESO, INC.					+37.35%
	SUMMIT THERAPEUTICS INC.					+72.24%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.15%
	MADRIGAL PHARMACEUTICALS, INC.					-0.84%
	Average					+24.26%
	Weighted average by Cap.					+20.75%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,056.00DKK

Average target price

2,083.23DKK

Spread / Average Target

+1.32%

High Price Target

3,060.00DKK

Spread / Highest target

+48.83%

Low Price Target

1,015.00DKK

Spread / Lowest Target

-50.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Kepler Cheuvreux
alphavalue	Anas Patel
Truist Securities
Jyske Bank
Baptista Research
RBC Capital Markets
Nordea Bank
Svenska Handelsbanken
Bernstein
William Blair & Co.
Leerink Partners
BNP Paribas
Redburn Atlantic
BMO Capital
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group